Sunshine Biopharma's Q2 Loss Deepens as ATM Sales Add $1.7M and Warrant Overhang Expands
SBFM is trading near its 52-week low of $1.1 (5.5% above the low) on light trading volume (0.1× avg).
Summary
Q2 loss narrows slightly but gross margin falls sharply; ATM sales and warrant adjustments add significant dilution risk.
Key Events · Earnings and Guidance · SBFM
-
Q2 Net Loss of $1.56M
Revenue fell 1.6% to $9.26M while gross margin dropped to 26.2% from 36.4%, driving a net loss of $1.56M ($1.15 per share).
-
ATM Sales Raise $1.72M
From July 27 to August 12, 2026, the company sold 1,430,521 shares under its $4M ATM program for $1,722,555 in net proceeds.
-
Series B Warrant Overhang Expands
ATM sales triggered an adjustment to 25,477,133 Series B warrants at $1.2202 per share, versus 3.88M shares outstanding.
-
Director Compensation in Stock
On August 7, 2026, the company issued 58,300 shares to a director for services, adding to dilution.
Analysis · SBFM · Life Sciences
The Q2 2026 10-Q reveals a net loss of $1.56 million on revenue of $9.26 million, with gross margin compressed to 26.2% from 36.4% a year earlier. A $5.1 million public offering in May was followed by sales of 1.43 million shares under the $4 million ATM, generating $1.72 million in net proceeds. Those ATM sales triggered a Series B warrant adjustment to 25.5 million warrants at $1.22, creating a massive overhang relative to the 3.88 million shares outstanding. Management estimates a cash runway of 27 months, but the warrant structure and continued losses suggest further dilution is likely.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1605 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.53%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SBFM was trading at $1.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.9M. The 52-week trading range was $1.10 to $24.30. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.